Clinicopathological features and therapeutic advances in primary pulmonary lymphoepithelioma‑like carcinoma (Review)
Oncology Letters · 25.06.2026 · 32 (2) · 1-11
DOI: 10.3892/ol.2026.15728 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Oncology Letters, online erschienen am 25.06.2026. Verfasst von Yong Chen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, The Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, P.R. China. Die Arbeit nennt 88 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Primary pulmonary lymphoepithelioma-like carcinoma (PPLELC) is a rare subtype of non-small cell lung cancer, the clinicopathological features and molecular mechanisms of which are markedly different from those of other lung cancer subtypes.In recent years, with in-depth research in molecular pathology and immunology, notable progress has been achieved in the pathogenesis, diagnostic methods and therapeutic strategies of PPLELC.Epidemiological studies have shown that PPLELC is closely associated with Epstein-Barr virus (EBV) infection and the role of EBV in tumorigenesis has become a particular research focus.In addition, the unique immune microenvironment characteristics of PPLELC provide potential targets for immunotherapy.The present review systematically summarizes the epidemiology, pathological features, molecular biological mechanisms and diagnostic methods of PPLELC and focuses on discussing the association between EBV infection and tumorigenesis, the characteristics of immune microenvironment, as well as the latest advances in targeted therapy and immunotherapy.The aim was to provide a comprehensive diagnostic and therapeutic framework for clinicians and to prospect future research directions.Contents 1. Introduction 2. Epidemiology and clinical features 3. Pathological features and diagnosis 4. Molecular biological characteristics 5. Differential diagnosis 6. Treatment strategies 7. Advances in targeted therapy and immunotherapy 8. Prognostic factors and follow-up 9. Conclusions and future perspectives
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Respiratory and Critical Care Medicine, The Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, P.R. China.
- Nursing Department, The Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, P.R. China.
- Department of Respiratory and Critical Care Medicine, Clinical Medical College and Affiliated Hospital of Chengdu University, Chengdu, Sichuan 610081, P.R. China.
- Department of Respiratory and Critical Care Medicine, Sichuan Friendship Hospital, Chengdu, Sichuan 610066, P.R. China.
Zitieren
APA
Chen, Y., Yu, Y., & Chen, X. (2026). Clinicopathological features and therapeutic advances in primary pulmonary lymphoepithelioma‑like carcinoma (Review). Oncology Letters, 32(2), 1-11. https://doi.org/10.3892/ol.2026.15728
Vancouver
Chen Y, Yu Y, Chen X. Clinicopathological features and therapeutic advances in primary pulmonary lymphoepithelioma‑like carcinoma (Review). Oncology Letters. 2026;32(2):1-11. doi:10.3892/ol.2026.15728
BibTeX
@article{Chen2026,
author = {Chen, Yong and Yu, Yonglin and Chen, Xiaoju},
title = {Clinicopathological features and therapeutic advances in primary pulmonary lymphoepithelioma‑like carcinoma (Review)},
journal = {Oncology Letters},
year = {2026},
volume = {32},
number = {2},
pages = {1--11},
doi = {10.3892/ol.2026.15728}
}
EUVIMED